Ensitrelvir Datasheet DC Chemicals

Description	Ensitrelvir, also known as S-217622, is an antiviral drug developed by Shionogi in partnership with Hokkaido University, which acts as an orally active 3C-like protease inhibitor for the treatment of COVID-19 infection. It is taken by mouth, and has been successfully tested against the recently emerged Omicron variant. It is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM). It became the first Japanese domestic pill to treat COVID-19, third to be regulatorally approved in Japan; in February 2022.
Cat.No	DC74875
Name	Ensitrelvir

Chemical Properties

CAS	2647530-73-0
Formula	C22H17CLF3N9O2
MW	531.884
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

References

Return Policy

If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.

Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.

Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com